Hybrisens Limited

Hybrisens Limited

Early Stage Company with Platform Technology

Purpose :
To develop new versions of proven protein drugs, with reduce
adverse side effects and better clinical utility.

Platform Technology :
Patented molecular configuration for creating ``Chimeric``
protein - drugs - proven protein therapeutics genetically fused
to naturally induced immuno-protective molecules which resist
elimination from the blood. This extends the drug`s Half-life by
several orders of magnitude, improves its effectiveness, and
reduces toxicity.

Patents :
Issued in the U.S., Canada, Britain and the Commonwealth, the
European Community; pending in Japan.

Products :
Under development, chimeric versions of interleukin (IL-2, IL-6).

Disease Indications :
Renal cell (Kidney) carcinoma, melanoma (skin) cancer, AIDS.

Financial :
Founded in 1986, the company has maintained profitability over
the last four years through income from contract R&D for academic
institutions and pharmaceutical companies.

Management :
Experienced management team supported by distinguished scientific
advisers.

Facilities :
Well equipped and fully supported laboratory, located at York
University campus.

Ownership :
Private, with the following as major shareholders :
Innovation Ontario - a provincial crown corporation - 35%
MABS - Small Business Development Corporation - 28%
Current and former management and employees - 37%


KEY POINTS
* Platforms technology, with established ``proof-of-principle``
and core patent in over 20 countries.
* Experienced management team with proven track record of
maintaining profitability.
* Well-defined, potential market for cancer therapeutic the first
two indications mentioned above currently estimated at U$
580,000,000.
* Products entering final stages of preclinical development.
* Established growth strategy and business plan, with clear
targets for completing preclinical-phase for chimeric-IL-2 within
two years.
* Potential to increase shareholders value significantly in the
near future.

Company Details

Year Established: 1986

Number of Employees: 5

Company Information

Ezekiel Shami
Title: Data Provider
Telephone: (416) 736-5504
Fax: (416) 736-5979

Products

Early Stage Company With Platform Technology

Interleukin (il-2, Il-6).
Product under development, chimeric versions of interleukin (IL-2, IL-6).

Services

Biotechnology